LockSeq - Enabling Routine and Streamlined gene editing outcome characterization for cell & gene therapy development and validation
| Reference number | |
| Coordinator | Countagen AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | October 2025 - May 2026 |
| Status | Ongoing |
| Venture | Innovative Startups |
| Call | Innovative Startups 2025 |
Purpose and goal
The project aims to (i) validate LockSeq´s unique value propositions by running pilot studies with end-users from the NIST Genome Editing Consortium and GeneHumiDi COST network, and (ii) develop a scalable business model and pricing strategy. This will provide end-user proof points for LockSeq´s technical and commercial value.
Expected effects and result
The project will deliver end-user validation for the LockSeq platform, confirming its technical and commercial value. This provides the foundation for our scalable business case. The expected effect is enabling routine, high-resolution gene editing characterization, which accelerates development cycles for gene therapies.
Planned approach and implementation
The project is structured in two work packages (WPs). WP1 (Oct 2025 - Feb 2026) focuses on end-user validation by offering pilot services and prototype kits and software and conducting at least 5 pilot studies. WP2 (Mar 2026 - May 2026) focuses on developing the business model, including conducting ≥20 customer interviews and defining the pricing strategy and commercialization plan.